Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Study: Hydroxychloroquine not warranted for hospitalized COVID-19 patients 

By Brian Buntz | November 11, 2020

Hydroxychloroquine

[Image courtesy of Wikipedia]

A National Institutes of Health clinical trial has concluded that hydroxychloroquine had no clinical benefit for hospitalized COVID-19 patients.

The Journal of the American Medical Association published the results from the blinded, placebo-controlled, randomized trial.

The clinical trial, known as the “ORCHID” study, treated 479 symptomatic COVID-19 patients with hydroxychloroquine in 34 hospitals in the U.S. Clinical trial volunteers received either 10 doses of hydroxychloroquine or a placebo for five days. Researchers then evaluated their clinical status 14 days after the completion of the treatment phase.

Researchers found that the placebo and hydroxychloroquine arms had similar trial outcomes, which took place from April 2 and June 19, 2020. The findings “do not support the use of hydroxychloroquine for treatment of COVID-19 among hospitalized adults,” the study authors concluded.

Hydroxychloroquine, an anti-malarial drug, had come into prominence earlier this year after in vitro studies showed promise against the novel coronavirus. By April, U.S. President Trump began advocating hydroxychloroquine as a COVID-19 treatment.

Clinical evidence regarding the drug was less promising. One study published in the New England Journal of Medicine, for instance, found that hospitalized COVID-19 patients treated with the medication were slightly less likely to be discharged from the hospital than patients receiving the standard of care.

The White House would later order that HHS add 23 million hydroxychloroquine tablets to the Strategic National Stockpile as a potential COVID-19 treatment. The President reportedly pressured the FDA to grant an EUA for the drug, which the agency later revoked.

Tell Us What You Think! Cancel reply

Related Articles Read More >

FDA logo
FDA prevented 317 drug shortages in 2021
Pfizer-BioNTech vaccine vial
Pfizer, BioNTech moving forward on seeking COVID-19 vaccine EUA for youngest children
FDA logo
FDA curtails use of Janssen COVID-19 vaccine over blood clotting concerns
FDA logo
FDA sends warning letters to CBD and delta-8 THC product vendors

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards